Progression-free survival was significantly longer in the bevacizumab and capecitabine group than in the bevacizumab only group ( median 119 months [ 95 % CI 98-154 ] vs 43 months [ 39-68 ] ; stratified hazard ratio 038 [ 95 % CI 027-055 ] ; two-sided log-rank p < 00001 ) , as was overall survival ( median 390 months [ 95 % CI 323-not reached ] vs 237 months [ 185-317 ] ; stratified HR 043 [ 95 % CI 026-069 ] ; two-sided log-rank p = 00003 ) .